Efficacy and safety of calcineurin inhibitor treatment for IgA nephropathy: a meta-analysis

• Published in: BMC nephrology Vol. 18; no. 1; p. 61
• Main Authors: Song, Yu-Huan, Cai, Guang-Yan, Xiao, Yue-Fei, Wang, Yi-Ping, Yuan, Bao-Shi, Xia, Yuan-Yuan, Wang, Si-Yang, Chen, Pu, Liu, Shu-Wen, Chen, Xiang-Mei
• Format: Journal Article
• Language: English
• Published: England BioMed Central 13.02.2017
• Subjects: Calcineurin Inhibitors - therapeutic use; Causality; Drug-Related Side Effects and Adverse Reactions - diagnosis; Drug-Related Side Effects and Adverse Reactions - epidemiology; Female; Gastrointestinal Diseases - epidemiology; Glomerulonephritis, IGA - diagnosis; Glomerulonephritis, IGA - drug therapy; Glomerulonephritis, IGA - epidemiology; Hirsutism - diagnosis; Hirsutism - epidemiology; Humans; Immunosuppressive Agents - administration & dosage; Male; Nephrology; Nervous System Diseases - diagnosis; Nervous System Diseases - epidemiology; Prevalence; Risk Factors; Treatment Outcome; Cyclosporine A; Calcineurin inhibitor; IgA nephropathy; Tacrolimus

IgA nephropathy is the most common progressive glomerular disease to end stage renal failure worldwide. Calcineurin inhibitors (CNIs) is a selective immunosuppressant widely used in organ transplantation. The efficacy and safety of calcineurin inhibitors for the treatment of IgA nephropathy remain u...